Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will participate in the following upcoming investor conferences:
23rd Annual Needham Virtual Healthcare Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 11th at 11:45 am Eastern Time (ET).
Canaccord Genuity Horizons in Oncology Virtual Conference: Zymeworks' management will participate in virtual one-on-one meetings and a panel discussion on April 15th at 3:00 pm ET.
Stifel Virtual Targeted Oncology Days Conference: Zymeworks' management will participate in virtual one-on-one meetings and present on April 16th at 12:30 pm ET.
2024 Bloom Burton & Co. Healthcare Investor Conference: Zymeworks' management will participate in one-on-one meetings and present on April 16th at 2:00 pm ET.
Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetrictm technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibody therapeutics across multiple novel targets in indications that represent areas of significant unmet medical need. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Evolv Technology , the leading security technology company pioneering AI-based screening to create safer experiences, today announced its partnership with Belmont University. Located in Nashville, Tennessee, the university began using Evolv Express®...
Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") , today announced that it has filed an application with the Supreme Court of British Columbia for summary determination in its ongoing litigation with Verano...
Accurate gender representation in advertising is driving measurable business outcomes for brands?such as heightened consumer trust, loyalty and, most importantly, improved sales performance?according to SeeHer's latest Gender Equality Measure (GEM®)...
Structured Database/Data Management workloads continued to drive the largest share of enterprise IT infrastructure spending in the second half of 2023 (2H23), according to the International Data Corporation (IDC) Worldwide Semiannual Enterprise...
Since its strategic merger with Blue Rabbit in June 2023, Wedgewood has evolved its position as the nation's leading veterinary compounding pharmacy to become a comprehensive veterinary pharmacy solutions provider. Today, the combined company...
Hahn, a leading predictive marketing and PR agency, has been named the 2024 Digital PR Agency of the Year by PRovoke Media. The award is one of the most prestigious and competitive in the marketing and PR industry and recognizes Hahn's commitment to...